



AN EXCEPTIONAL TWO-DAY EVENT NOT TO BE MISSED!

24 - 25 February 2016
 Hotel Le Plaza
 Brussels, Belgium

EURORDIS and partners will bring together all stakeholders in the rare disease field to discuss the current state of play and how to shape a more effective way to address **value determination, appraisal, pricing** and **reimbursement** of orphan medicines with an aim to **improve patients' access** to rare disease therapies throughout Europe.



Please note
 that registration
 is required for
 this event



WHO CAN ATTEND?

Pharmaceutical and
 biotech industry leaders

Patient representatives

Payers (HTA agencies
 and National Competent
 Authorities)

Policy makers

Regulators

Consultants

Investors

Health care professionals

Academics

and Researchers...



WHY ATTEND?

✓
Learn

about the key
 challenges to access for
 rare disease therapies

✓
Gain

common understanding
 on what is value and
 the current ways
 it is determined

✓
Understand

regulatory initiatives
 to address the gap
 between authorisation
 and access

✓
Explore

emerging pricing,
 reimbursement and
 access processes with
 those responsible
 for the markets to
 recognise which
 work best

✓
Hear

how HTA agencies
 assess advanced
 therapies and very
 rare diseases

✓
Be challenged

to evaluate and price
 orphan medicinal
 products from
 different stakeholder's
 perspectives, via
 on-site simulation
 exercises

✓
Agree

on a structured
 approach forward
 and set of solutions
 to explore

IN PARTNERSHIP WITH



For more information,
 and to register,

please visit our dedicated
[EURORDIS webpage](http://eurordis.org).

If you have any questions, do not
 hesitate to contact Anne-Mary Bodin
 at anne-mary.bodin@eurordis.org